The Hellenic Competition Commission is set to convene to examine whether Novartis has violated competition laws by implementing a comprehensive strategy to exclude competitive drugs from the market for treating ophthalmic diseases.

Novartis is accused of employing various practices such as naked restrictions and denigration to exclude competitors' drugs and increase prescriptions of its own products, causing harm to public entities, competitors, and consumers.

The alleged anticompetitive strategy was reportedly in place for nine years, from 2009 to 2017, during which Novartis held a dominant position in the Greek market for ophthalmic drugs.

The Investigator's Report is not binding, and the Hellenic Competition Commission will make a decision after considering all relevant data and opinions.